RxDoctor Payments Data

Celina Doyle

Acute Care · Las Cruces, NMNPI 1659036317

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Grifols USA, LLC at 27.9% of the total. Reporting peaked in 2024 at $213 and has fallen 81.4% since, to $40 in 2025.

$403in general payments, 2019–2025

Across 15 payments — averaging $26.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Grifols USA, LLC$112
  • Corcept Therapeutics$93
  • Corium, LLC$69
  • Bayer$46
  • Insulet Corporation$35
  • Lilly USA, LLC$18
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$403100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$403 in reported general payments places this provider in the 60th percentile of 132 acute care providers in New Mexico.

See all acute care providers in New Mexico

Medicare billing

Part B allowed, 2024
$17,600
Medicare patients
164
Services billed
177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluticasone Propionate57$825
Ondansetron OdtOndansetron31$307
Albuterol Sulfate HfaAlbuterol Sulfate12$307
Methocarbamol49$238
Diclofenac Sodium25$221
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav21$173
Ibuprofen31$165
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim21$146
Doxycycline Hyclate13$112
Cephalexin11$96
Azithromycin17$87
Dicyclomine Hcl16$80
Tramadol Hcl12$53
Prednisone22$46
Meloxicam13$33

Paid to pharmacies, not to this prescriber.

Other acute care in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →